资讯

Targeted Oncology2 天
FDA Receives New Drug Application for Ziftomenib in NPM1-Mutant R/R AML
Ziftomenib’s FDA application for relapsed/refractory NPM1-mutant acute myeloid leukemia is supported by data from the ...
Kura Oncology, Kyowa Kirin announce submission of NDA for ziftomenib to FDA
Kura Oncology (KURA) announced Kura submitted a New Drug Application for ziftomenib, a highly selective, once-daily, oral, investigational ...
来自MSN6 个月
Failure in a CAR T cell trial could unlock multiple treatments for acute myeloid leukemia
However, translating this success to acute myeloid leukemia (AML ... study evaluates the safety and efficacy of CART-123 in adult patients with relapsed or refractory AML. The study enrolled ...
Opinion
Sacramento doctor: If not for NIH funding, I wouldn’t have survived my leukemia diagnosis ...
My survival is based on research. With limited NIH funding, I fear that my life, and the lives of others, will be left without hope.” ...
Fred Hutch6 年
Soheil Meshinchi, MD, PhD
Soheil Meshinchi is an expert in leukemia biology, peripheral blood stem cell transplantation for children with leukemia, management of post-transplant relapse and targeted therapies for acute myeloid ...
Yahoo26 天
Sacramento doctor: If not for NIH funding, I wouldn’t have survived my leukemia diagnosis ...
Acute myelogenous leukemia (AML) is seen in this stock image. Duke researchers have discovered a new combination of drugs that is more effective than chemotherapy at killing acute myeloid leukemia ...